Efficacy and safety of ofloxacin in the treatment of nongonococcal sexually transmitted disease

Article Abstract:

The effectiveness of the antibiotics doxycycline and ofloxacin in treating infections with the bacteria Chlamydia trachomatis was evaluated in 30 men and 34 women. Eighteen men had nongonococcal urethritis, which is an inflammation of the urethra, the canal for the discharge of urine, whereas 12 men had previous infections with Chlamydia. Eleven women had mucopurulent cervicitis, the inflammation of the cervix, associated with the discharge of mucus and pus; 14 had previous Chlamydial infection, and nine had had sexual contact with men known to have chlamydial urethritis. There were no significant differences in the results in patients treated with doxycycline and ofloxacin. Among men, symptoms were eliminated within 21 to 28 days after therapy. Although the mucopurulent cervicitis in 13 women resolved within five to nine days after treatment, signs of recurrent cervicitis were seen in two women treated with doxycycline and one woman treated with ofloxacin. All patients showed no evidence of Chlamydial infection within five to nine days after treatment, although one patient treated with doxycycline had signs of Chlamydial infections 21 to 28 days after therapy. The results show that the new quinolone antibiotic ofloxacin is as effective as doxycycline in treating chlamydial infections. Doxycycline and ofloxacin are equally effective in treating nongonococcal urethritis in men and mucopurulent cervicitis in women. (Consumer Summary produced by Reliance Medical Information, Inc.)

Doxycycline, Cervicitis, Urethritis, Nongonococcal, Nongonococcal urethritis

---

Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections

Article Abstract:

The effectiveness of the fluoroquinolone antibiotic, ofloxacin, in treating infections caused by Chlamydia pneumoniae was assessed in patients with lower respiratory tract infections (either pneumonia or bronchitis). There were six patients with infections caused by C. pneumoniae, and four received 400 milligrams (mg) ofloxacin given twice a day while two patients received 400 mg erythromycin, another antibiotic, given four times a day. The patients were treated for a period of 10 days. All four patients treated with ofloxacin were completely cured, or improved significantly, within two weeks of starting treatment with ofloxacin. Of the two patients treated with erythromycin, one was cured and the other was improved. It had been determined that the lowest dose of ofloxacin required to prevent the growth of C. pneumoniae ranged from 1.0 to 2.0 micrograms per milliliter. This blood level of antibiotic can easily be reached using the treatment regimen of 400 mg oral ofloxacin twice daily. These findings suggest that treatment with the fluoroquinolone antibiotic ofloxacin may be an effective alternative to conventional therapy with erythromycin in patients with respiratory infections caused by C. pneumoniae. (Consumer Summary produced by Reliance Medical Information, Inc.)

Respiratory tract infections

---

In vitro activity of ofloxacin against Chlamydia trachomatis

Article Abstract:

The effect of the quinolone antibiotic ofloxacin on Chlamydia trachomatis, the most common sexually transmitted bacteria, was examined in 27 isolates, bacterial samples isolated from persons infected with the bacteria. The bacterial isolates were obtained from eight different metropolitan areas in the United States. Less than one microgram per milliliter (ug/ml) of ofloxacin prevented the growth of C. trachomatis in all 27 isolates tested. One microgram or less of the antibiotic had a bactericidal effect or killed off the bacteria in 26 of 27 isolates. The 90 percent minimal inhibitory concentration (MIC 90) of ofloxacin is defined as the smallest amount of the antibiotic that will prevent the growth of 90 percent of the bacteria. Thus the lower the MIC 90 value, the more susceptible the bacteria is to the antibacterial action of the drug. Studies have shown that the MIC 90 of ofloxacin was less than 0.1 ug/ml for Neisseria gonorrhoeae, less than two ug/ml for Haemophilus ducreyi, and eight to 25 ug/ml for Ureaplasma urealyticum. These results suggest that ofloxacin may be useful for treating bacterial sexually transmitted diseases, particularly for combined infections with chlamydiae and gonococci. (Consumer Summary produced by Reliance Medical Information, Inc.)

Quinolones

Similar abstracts:

• Abstracts: Resistance to ciprofloxacin appearing during therapy. Efficacy and safety of higher-dose intravenous ciprofloxacin in severe hospital-acquired infections
• Abstracts: Safety of intravenous ciprofloxacin. Safety of oral ciprofloxacin: an update based on clinical trial results. Ciprofloxacin: toxicologic evaluation of additional safety data
• Abstracts: Ofloxacin versus vancomycin/polymyxin for prevention of infection in granulocytopenic patients. Introduction: ofloxacin (Symposium: Ofloxacin: a pharmacodynamic advance in quinolone antimicrobial therapy)

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.